First Quadrant’s Akebia Therapeutics AKBA Stock Holding History

First Quadrant’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-5,262	Closed	-$43K	–	698
2019 Q1	$43K	Buy	+5,262	New	+$36.1K	﹤0.01%	646

Other funds holding AKBA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Quadrant's AKBA Position: Q2 2019 in Review

First Quadrant sold out of Akebia Therapeutics (AKBA) in Q2 2019, closing a stake of 5,262 shares — an estimated $43K sold.

First Quadrant first reported a position in AKBA in Q1 2019 and held it in 1 quarter. The position peaked at $43K in Q1 2019. 151 funds tracked by Wall St. Rank hold AKBA as of Q2 2019.

First Quadrant reported no remaining Akebia Therapeutics position as of Q2 2019 after selling out during the quarter.
First Quadrant sold 5,262 Akebia Therapeutics shares in Q2 2019, an estimated $43K.
First Quadrant first reported a position in Akebia Therapeutics in Q1 2019 and held it in 1 quarter.
First Quadrant's Akebia Therapeutics position peaked at $43K in Q1 2019.
151 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2019.

Based on First Quadrant's 13F filing for Q2 2019, filed 24 Jul 2019.